Legal & General Group
ADMA icon

Legal & General Group’s ADMA Biologics ADMA Stock Holding History

Legal & General Group’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.58M Sell
547,599
-55,108
-9% -$502K ﹤0.01% 1636
2026
Q1 		$5.43M Sell
602,707
-60,655
-9% -$957K ﹤0.01% 1463
2025
Q4 		$12.1M Sell
663,362
-30,782
-4% -$519K ﹤0.01% 1067
2025
Q3 		$10.2M Sell
694,144
-19,432
-3% -$333K ﹤0.01% 1205
2025
Q2 		$13M Buy
713,576
+37,699
+6% +$769K ﹤0.01% 1056
2025
Q1 		$13.4M Sell
675,877
-160,973
-19% -$2.78M ﹤0.01% 980
2024
Q4 		$14.4M Buy
836,850
+164,013
+24% +$3.09M ﹤0.01% 973
2024
Q3 		$13.5M Buy
672,837
+438,527
+187% +$6.82M ﹤0.01% 1017
2024
Q2 		$2.62M Buy
234,310
+10,904
+5% +$91.5K ﹤0.01% 1824
2024
Q1 		$1.47M Buy
223,406
+42,025
+23% +$230K ﹤0.01% 2049
2023
Q4 		$820K Buy
181,381
+4,876
+3% +$18K ﹤0.01% 2269
2023
Q3 		$632K Buy
176,505
+14,862
+9% +$57.2K ﹤0.01% 2343
2023
Q2 		$596K Buy
161,643
+84,565
+110% +$313K ﹤0.01% 2402
2023
Q1 		$255K Buy
77,078
+7,883
+11% +$27.3K ﹤0.01% 2497
2022
Q4 		$268K Buy
69,195
+49,722
+255% +$153K ﹤0.01% 2500
2022
Q3 		$47K Sell
19,473
-7,317
-27% -$17.6K ﹤0.01% 2984
2022
Q2 		$53K Buy
+26,790
New +$52.7K ﹤0.01% 2995
2021
Q2 		– Sell
-7,063
Closed -$12K – 3479
2021
Q1 		$12K Hold
7,063
– – ﹤0.01% 3319
2020
Q4 		$14K Hold
7,063
– – ﹤0.01% 3212
2020
Q3 		$17K Sell
7,063
-3,397
-32% -$9.31K ﹤0.01% 3016
2020
Q2 		$31K Hold
10,460
– – ﹤0.01% 2876
2020
Q1 		$30K Buy
10,460
+335
+3% +$1.16K ﹤0.01% 2757
2019
Q4 		$41K Buy
10,125
+1,748
+21% +$7.62K ﹤0.01% 2887
2019
Q3 		$37K Buy
8,377
+3,362
+67% +$14.1K ﹤0.01% 2863
2019
Q2 		$19K Buy
5,015
+2,204
+78% +$9.73K ﹤0.01% 3206
2019
Q1 		$11K Hold
2,811
– – ﹤0.01% 3234
2018
Q4 		$7K Hold
2,811
– – ﹤0.01% 3301
2018
Q3 		$17K Hold
2,811
– – ﹤0.01% 3244
2018
Q2 		$13K Buy
+2,811
New +$14K ﹤0.01% 3271

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Legal & General Group's ADMA Position: Q2 2026 in Review

Legal & General Group reduced its ADMA Biologics (ADMA) stake by 9.1% in Q2 2026, selling an estimated $502K and leaving 547,599 shares worth $4.58M. The position accounts for ﹤0.01% of the portfolio, ranked #1636.

Legal & General Group first reported a position in ADMA in Q2 2018 and has held it in 29 quarters since. The position peaked at $14.4M in Q4 2024. 322 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Legal & General Group held 547,599 shares of ADMA Biologics worth $4.58M as of Q2 2026.
  • Legal & General Group sold 55,108 ADMA Biologics shares in Q2 2026, an estimated $502K.
  • ADMA Biologics made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #1636 holding.
  • Legal & General Group first reported a position in ADMA Biologics in Q2 2018 and has held it in 29 quarters since.
  • Legal & General Group's ADMA Biologics position peaked at $14.4M in Q4 2024.
  • 322 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.